Passport by Molina Healthcare, the Medicaid managed care plan in Kentucky, does not cover weight loss medication when the prescription is primarily for weight loss, anorexia, or weight gain. The plan’s own materials put it plainly: “Drugs used for anorexia, weight loss, or weight gain are excluded from coverage.”1Molina Healthcare. GLP-1 Medication Policy Update That means brand-name anti-obesity drugs such as Wegovy and Saxenda cannot be filled through Passport if the reason for the prescription is obesity treatment alone. Some of the same molecules can be covered when they are prescribed for a different, qualifying medical condition, which is where most members find a path forward.
The Exclusion in Plain Terms
Passport follows Kentucky Medicaid’s Preferred Drug List and coverage rules. The member-facing summary notes that “some drugs for weight loss or cosmetic purposes” are not covered, and the provider policy is broader, excluding drugs used for weight loss, weight gain, or anorexia regardless of brand.2Molina Healthcare. Prescription Drugs – Kentucky Medicaid1Molina Healthcare. GLP-1 Medication Policy Update The exclusion is written into state Medicaid rules, not just the plan’s choices, and reflects a longstanding federal provision that lets state Medicaid programs exclude weight loss drugs from their pharmacy benefit.3KFF. Medicaid Coverage of and Spending on GLP-1s
What this looks like in practice: if your doctor writes a prescription for Wegovy, Saxenda, or a similar drug with obesity listed as the only reason, the pharmacy claim will be rejected. A different diagnosis on the prescription changes the analysis, because federal law still requires Medicaid to cover FDA-approved drugs for their other approved uses.
GLP-1 Medications Passport Will Cover, and When
Several of the drugs people associate with weight loss are covered by Passport and Kentucky Medicaid, but only for specific non-obesity diagnoses. Each pathway requires prior authorization, specialist involvement, and clinical documentation.
Type 2 Diabetes
Passport’s formulary includes GLP-1 receptor agonists such as Ozempic, Trulicity, Victoza, and Mounjaro when they are prescribed to treat Type 2 diabetes. A documented diabetes diagnosis is required, and the member generally has to show a trial of other diabetes medications such as metformin before approval. Prior authorization applies in every case.
Cardiovascular Risk and Liver Disease (Wegovy)
Kentucky Medicaid established prior authorization criteria for Wegovy effective January 3, 2026, under two non-obesity pathways.4MedImpact. Wegovy PA Criteria The first is to reduce the risk of major adverse cardiovascular events in patients aged 45 or older with a BMI of at least 27 and documented cardiovascular disease, such as a prior heart attack, stroke, or symptomatic peripheral arterial disease. The second is to treat metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis in adults aged 18 and older. Specialist involvement, lifestyle modifications, and clinical documentation are required. Patients with Type 2 diabetes or an A1c of 6.5% or higher are excluded from Wegovy coverage under these criteria.
Obstructive Sleep Apnea (Zepbound)
Zepbound has been covered under Kentucky Medicaid since July 1, 2025, for moderate to severe obstructive sleep apnea in adults with obesity.5MedImpact. Zepbound PA Criteria To qualify, you must be 18 or older with a BMI of 30 or greater, have a sleep study confirming moderate to severe OSA, and have tried and failed a CPAP or similar device for at least three months. The prescriber must be a sleep specialist or neurologist. Patients with a history of diabetes are excluded from this pathway. Approvals last six months and renewal requires demonstrated improvement, meaning either a meaningful reduction in sleep apnea severity or at least 5% weight loss from baseline.
A third anti-obesity drug, Brinsupri, also appears on the Kentucky Medicaid portal’s prior authorization list as of April 2026, though the clinical criteria were not detailed in the available documents.6MedImpact. Drug Information – Kentucky Medicaid Client Portal
What Passport Offers Instead for Weight Management
In place of weight loss medication, Passport offers a value-added benefit covering up to 13 weeks of the Weight Watchers digital program at no cost for eligible members aged 18 and older. You need doctor approval and must meet specific BMI requirements. Nutritional counseling is also listed as a covered benefit.7Molina Healthcare. Passport by Molina Healthcare Benefits Neither replaces a prescription drug benefit, but both are available without the clinical hurdles the GLP-1 pathways require.
How to Check Whether a Specific Drug Is Covered
To confirm coverage for a particular medication, search the Kentucky Medicaid formulary through the MedImpact Member Portal or call MedImpact Member Services at (800) 210-7628, which is available around the clock.2Molina Healthcare. Prescription Drugs – Kentucky Medicaid The portal shows whether a drug requires prior authorization, has quantity limits, or is subject to step therapy. Have the drug name, strength, and your prescriber’s information ready. If you are pursuing one of the non-obesity pathways above, your provider will need to submit the clinical documentation the criteria call for.
If Your Prescription Is Denied
A denial comes with a letter explaining the reason. Sometimes the problem is missing paperwork from the prescriber, and a resubmission with the right documentation resolves it. You and your provider both have the right to file a formal appeal, which a Molina physician reviews. If the appeal is denied, the decision letter will describe your next options, including requesting a state fair hearing.8Molina Healthcare. Molina Healthcare Pharmacy Services – Appeals Process One practical step before or during an appeal: ask your provider whether a covered alternative drug or dosage would work, or whether a non-obesity diagnosis that fits your clinical picture could support one of the prior authorization pathways.
Keep in mind that if the denial is because the prescription was written for weight loss, no amount of additional paperwork changes the outcome under the current exclusion. The appeal has to point to a covered use.
What Could Change
Kentucky has been reconsidering its blanket exclusion. The Cabinet for Health and Family Services proposed amending regulation 907 KAR 23:010 to allow Medicaid reimbursement for drugs used for weight loss, anorexia, and weight gain, with access managed through prior authorization, step therapy, and manufacturer rebates. The public comment period closed in November 2025.9Kentucky Legislative Research Commission. 907 KAR 23:010 Proposed Amendment At a February 2026 oversight hearing, Lisa Lee, Commissioner of the Department for Medicaid Services, said the state’s goal would be access for people with “underlying health conditions” rather than cosmetic use.10Spectrum News 1. State Mulls Expanding GLP-1 Access to More Medicaid Patients
Legislation moved in the opposite direction at the same time. House Bill 2, a broader Medicaid reform bill, originally sought to block coverage for drugs prescribed “primarily for weight loss or weight management purposes.” The Senate Health Services Committee narrowed the language to target only drugs prescribed “primarily for weight loss,” passing the amended version unanimously in late March 2026. Committee Chair Sen. Stephen Meredith described the bill as a “work in progress.”11Kentucky Lantern. KY Bill Making Sweeping Changes to Medicaid Program Adds Copays
At the federal level, a voluntary program called the BALANCE model launched in December 2025, letting state Medicaid agencies cover GLP-1s for weight management at negotiated lower prices through supplemental rebate agreements. States had until July 31, 2026, to apply. Kentucky’s participation status has not been publicly confirmed.12KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid Until any of this changes, the exclusion in Passport’s pharmacy benefit stands, and the non-obesity pathways described above are where coverage actually lives.